<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00384995</url>
  </required_header>
  <id_info>
    <org_study_id>PR021676</org_study_id>
    <nct_id>NCT00384995</nct_id>
  </id_info>
  <brief_title>Bicarbonate v Saline to Prevent Contrast Nephropathy</brief_title>
  <official_title>Phase 4 Study of Bicarbonate Versus Saline Infusion Therapy to Prevent Contrast Induced Nephropathy (CAN-IT PREVENT Protocol)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Italian Society of Nephrology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Memorial University of Newfoundland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Italian Society of Nephrology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Slowing of kidney function occurs in a minority of people given dye during angiography. The
      purpose of this study is to compare two different types of fluid given into a vein to reduce
      the risk of kidney injury: salt in water or baking soda in water.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A decline in kidney function after contrast is associated with prolonged hospital stay,
      adverse cardiac events, and higher mortality both in hospital and in the long term.
      Deliberate administration of fluids is recommended to reduce the risk of contrast
      nephropathy. However, data to support specific recommendations are lacking and the optimal
      fluid regimen remains unclear.

      It has been hypothesized that alkalinization of tubular fluid might be beneficial by reducing
      pH dependent free radical levels. A recent trial found a lower frequency of creatinine rise &gt;
      25% within two days of contrast with a 7 hour infusion of isotonic sodium bicarbonate than
      with saline infusion (Merten GJ, JAMA 2004). However, it remains to be proven that
      bicarbonate is superior as this trial has a number of methodological flaws.

      Comparison: IV 1/6 M sodium bicarbonate OR IV 0.9% saline, each isotonic fluid given at the
      same rate of sodium administration (3.25 ml/Kg over 1 hour pre-contrast, followed by 1.1
      ml/Kg/hr for 6 hours for bicarbonate; 3.5 ml/Kg over 1 hour pre-contrast, followed by 1.2
      ml/Kg/hr for 6 hours for saline). Total infusion time 7 hours (for both). Maximum rate of
      fluid permitted is that for a body weight of 110 Kg. Intra-vascular iso- or low-osmolality
      contrast in the minimal dose needed to complete the required imaging.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funding
  </why_stopped>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of contrast-induced nephropathy, CIN, defined as an increase in serum creatinine of 25% or more from pre-intervention baseline to within 48-72 hours after administration of the radiographic contrast.</measure>
    <time_frame>48-72 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Group mean change in serum creatinine</measure>
    <time_frame>48-72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in hospital within the week post contrast</measure>
    <time_frame>One week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement for dialysis</measure>
    <time_frame>Two months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atheroembolic events</measure>
    <time_frame>Two months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>Two months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Two months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Kidney Failure, Acute</condition>
  <condition>Contrast Media</condition>
  <arm_group>
    <arm_group_label>Bicarbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bicarbonate solution infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard volume expansion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% (154 mEq/L) IV Sodium Chloride</intervention_name>
    <description>Saline solution</description>
    <arm_group_label>Saline</arm_group_label>
    <other_name>Sodium Chloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1/6 M (166 mEq/L) IV Sodium Bicarbonate</intervention_name>
    <description>Bicarbonate solution</description>
    <arm_group_label>Bicarbonate</arm_group_label>
    <other_name>Sodium Bicarbonate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Booked for cardiac or other non-renal arteriography

          -  Pre-existing reduced kidney function: Serum Creatinine &gt;= 1.3 &amp; &lt;= 4 mg/dl (female
             gender) or &gt;= 1.5 &amp; &lt;= 5 mg/dl (male gender)

          -  Age &gt; 18 years

        Exclusion Criteria:

          -  GFR MDRD estimate &lt; 15 ml/min/m2

          -  End-stage renal disease already on dialysis

          -  Known current Acute Kidney Failure with serum creatinine rise of &gt; 0.5 mg/dl within 24
             hours

          -  Pulmonary edema - current or within 48 hours

          -  Clinically relevant ascites, edema or other fluid overload

          -  Uncontrolled hypertension (&gt; 165 mmHg systolic, or &gt; 105 mmHg diastolic)

          -  Hemodynamically unstable patient requiring IV nitroglycerine, or IV fluid or inotropes
             for blood pressure support

          -  Emergency (unplanned) angiography

          -  IV contrast procedure

          -  Exposure to iodinated radiocontrast within 3 days prior to study

          -  Prior anaphylactoid reaction to contrast

          -  Planned administration of N-acetylcysteine

          -  Planned administration of dopamine, fenoldopam or mannitol

          -  Current pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pietro Ravani, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Italian Society of Nephrology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brendan BJ Barrett, MD, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Memorial University of Newfoundland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ferruccio Conte, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Italian Society of Nephrology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Ferrarotto</name>
      <address>
        <city>Catania</city>
        <zip>95100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.O. Uboldo</name>
      <address>
        <city>Cernusco sul Naviglio</city>
        <zip>20063</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Istituti Ospitalieri di Cremona</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Donato</name>
      <address>
        <city>San Donato</city>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Merten GJ, Burgess WP, Gray LV, Holleman JH, Roush TS, Kowalchuk GJ, Bersin RM, Van Moore A, Simonton CA 3rd, Rittase RA, Norton HJ, Kennedy TP. Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. JAMA. 2004 May 19;291(19):2328-34.</citation>
    <PMID>15150204</PMID>
  </reference>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2006</study_first_submitted>
  <study_first_submitted_qc>October 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2006</study_first_posted>
  <last_update_submitted>November 29, 2010</last_update_submitted>
  <last_update_submitted_qc>November 29, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2010</last_update_posted>
  <responsible_party>
    <name_title>Pietro Ravani</name_title>
    <organization>Italian Society of Nephrology</organization>
  </responsible_party>
  <keyword>Contrast Induced Nephropathy</keyword>
  <keyword>Chronic Kidney Disease</keyword>
  <keyword>Acute Renal Failure</keyword>
  <keyword>End-stage Renal Disease</keyword>
  <keyword>Cardiovascular diseases</keyword>
  <keyword>Coronary catheterization</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Intra-arterial angiography</keyword>
  <keyword>Bicarbonate</keyword>
  <keyword>Saline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

